Drug intelligence / Profile preview

cyclosporin H

Development stage
Preclinical
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Oral
01

Overview

Cyclosporin H is a non-immunosuppressive cyclic undecapeptide and a diastereomer of the well-known immunosuppressant Cyclosporin A. Unlike Cyclosporin A, which binds to cyclophilin to inhibit calcineurin, Cyclosporin H lacks significant calcineurin-inhibiting activity. Instead, it acts as a potent and selective antagonist of the Formyl Peptide Receptor 1 (FPR1), a G protein-coupled receptor primarily expressed on neutrophils and macrophages. FPR1 plays a critical role in the innate immune response by sensing N-formyl peptides derived from bacteria or damaged mitochondria. By blocking FPR1, Cyclosporin H inhibits leukocyte chemotaxis and the production of reactive oxygen species. Recent research has demonstrated its potential protective effects in sepsis-associated acute kidney injury (SA-AKI) by modulating FPR1 signaling and inhibiting pyroptosis, making it a valuable pharmacological tool for studying FPR1-mediated inflammatory processes.

Other names
Cyclosporine HD-MeVal-1-cyclosporinD-MeVal1-cyclosporinD-MeVal 1-cyclosporin
02

Targets

FPR1 (Formyl peptide receptor 1)

Beyond the preview

Go deeper on cyclosporin H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporin H.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call